The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 03, 2007
Filed:
Oct. 04, 2002
Laura Carter, Medford, MA (US);
Beatriz Carreno, Acton, MA (US);
Leslie D. Lowe, Sudbury, MA (US);
Matthew J. Whitters, Hudson, MA (US);
Kyri Dunussi, Belmont, MA (US);
Mary Collins, Natick, MA (US);
Margery MA, W. Roxbury, MA (US);
Deborah A. Young, Melrose, MA (US);
Joann S. Witek, Acton, MA (US);
Glenn Larsen, Sudbury, MA (US);
Marion T. Kasaian, Charlestown, MA (US);
Debra D. Donaldson, Medford, MA (US);
Michelle Unger, Chapel Hill, NC (US);
Laura Carter, Medford, MA (US);
Beatriz Carreno, Acton, MA (US);
Leslie D. Lowe, Sudbury, MA (US);
Matthew J. Whitters, Hudson, MA (US);
Kyri Dunussi, Belmont, MA (US);
Mary Collins, Natick, MA (US);
Margery Ma, W. Roxbury, MA (US);
Deborah A. Young, Melrose, MA (US);
JoAnn S. Witek, Acton, MA (US);
Glenn Larsen, Sudbury, MA (US);
Marion T. Kasaian, Charlestown, MA (US);
Debra D. Donaldson, Medford, MA (US);
Michelle Unger, Chapel Hill, NC (US);
Genetics Institute, LLC, Cambridge, MA (US);
Abstract
Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor ('IL-21R' or 'MU-1'), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.